The ‘triple-negative breast cancer (TNBC)’, seen among 10–15% of patients, is the most challenging type of breast cancer and is characterised by a lack of expression of the estrogen receptor (ER), Progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2) [4]. This evidence concerns the gene ERBB2 and breast carcinoma.